

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD
QUAKERBRIDGE PLAZA, BUILDING 7, Rooms 200 ABC**

January 13, 2016

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

AGENDA

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of draft meeting summary for October 14, 2015 meeting
- IV. Secretary's report
- V. Old Business
 - A. HMO responses to DURB follow-up questions
 - B. Proposed protocol: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
- VI. New Business
 - A. Protocol review:
 1. Proton pump inhibitors (PPIs)
 2. Oxycodone Controlled Release (Oxycontin®)
- VII. Informational Highlights/Reports
 1. Molina/NJ HMO 3rd Quarter 2015 Prior Authorization Report
 2. Summary of DURB Action Items
 3. DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
 4. Medication information:
 - (a) New FDA Drug Safety Communication on Viekira Pak® and Technivie®
 - (b) FDA approves rare bleeding disorder therapy
 - (c) CDC Finds Nursing Home Residents Wrongly Prescribed Antibiotics Up To 75 Percent Of The Time
 - (d) FDA Approves Drug To Reverse Effect Of Anticoagulant